Trial Profile
Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Multicenter Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Cancer; Non-small cell lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors TOT Biopharm
- 16 Jun 2022 Status changed from recruiting to completed.
- 01 Dec 2021 According to TOT Biopharm media release, based on results from the pharmaceutical studies, non-clinical studies, and clinical studies Pusintin (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in mainland China (i.e., excluding Hong Kong, Macau and Taiwan regions) for the treatment of patients with advanced, metastatic or recurrent non-squamous NSCLC and patients with metastic colorectal cancer.
- 21 Apr 2020 According to TOT Biopharm media release, this study has recently reached the predefined primary endpoint. The Company will continue to push forward the new drug application (NDA) of TAB008 (Pusintin) as scheduled.